Epidermolysis Bullosa Acquisita: A Case Report of a Rare Clinical Phenotype and a Review of Literature

Cristina Beiu, Mara Mihai, Liliana Popa, Tiberiu Tebeica, Calin Giurcaneanu

1. Oncologic Dermatology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU. 2. Dermatopathology, Dr. Leventer Centre, Bucharest, ROU

Corresponding author: Cristina Beiu, cristina.popescu1990@yahoo.com

Abstract
Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal bullous disorder of the skin and mucous membranes. The disease results from the production of immunoglobulin G (IgG) antibodies against type-VII collagen, a major component of anchoring filaments in the dermal-epithelial junction. The disease has two major forms of presentation: the classical (non-inflammatory) type and the inflammatory type. Classical EBA is mainly characterized by the following features: development of non-inflammatory tense blisters on trauma-prone areas, multiple milia cysts, minimal or no inflammation findings on histopathology. Alternatively, inflammatory EBA is defined by widespread inflammatory blistering eruptions and a neutrophil-rich inflammatory infiltrate on standard histopathology. In both cases, specialized immunopathological findings are further required to establish an accurate diagnosis. In this article, we present an atypical case that shares features of both inflammatory and non-inflammatory forms of EBA. The case also serves to review and synthesize current concepts on the etiopathogenesis, diagnosis, and treatment of this extremely rare disease.

Categories: Dermatology, Internal Medicine, Pathology
Keywords: epidermolysis bullosa acquisita, blistering disorders, bullous diseases

Introduction
Epidermolysis bullosa acquisita (EBA) is an acquired, subepidermal mucocutaneous blistering disorder that results from autoimmunity to collagen VII, a main structural component of anchoring fibrils in the basement membrane zone (BMZ) of the dermal-epidermal junction (DEJ). The incidence of this rare disease is approximated at 0.2 per one million people and it usually affects middle-aged adults [1]. Anecdotally, the disease exhibits two main clinical and histopathological forms: non-inflammatory (also called ‘classical form’) and inflammatory EBA, the latter mimicking other subepithelial autoimmune blistering disorders [2].

This case illustrates an atypical clinical phenotype of EBA presenting with specific clinical findings of the classical form but with unequivocal histopathological features of inflammatory EBA. The case also serves to review classic and unexpected findings of the etiopathogenesis, diagnosis, and treatment of this extremely rare disease.

Case Presentation
A 54-year-old Caucasian male presented to our dermatology department for the evaluation of a mucocutaneous blistering eruption that had evolved over a period of three years. The eruption consisted of tense blisters that easily rupture to form painful erosions (Figure 1). Some of the older erosions had already healed with small atrophic scar areas and multiple milia cysts (Figure 2). The patient had complaints of increased skin fragility stating that the lesions were easily induced by minor injuries. The lesions were widespread but indeed had a predilection for areas that are regularly prone to repetitive trauma: palmoplantar area, elbows, knees, and posterior trunk. Physical examination additionally showed onychodystrophy with partial loss of the big right toenail (as seen in Figure 3) and moderate fibrosis of the fingers, with reduced hand mobility (Figure 4). The patient also suffered from concomitant mucosal involvement, with multiple oral erosions (Figure 5).

How to cite this article
FIGURE 1: Clinical image illustrating tense blisters (black arrows) and multiple erosions (green arrows) on the right palm.

FIGURE 2: Multiple milia cysts (yellow asterisk) developed on an older lesion on the elbow.
FIGURE 3: Marked onychodystrophy of the big right toenail (white arrow)

FIGURE 4: Fibrotic changes of the fingers; please notice the shiny and thickened aspect of the skin (white arrows)
Prior to referral in our clinic, the patient was initially diagnosed as having bullous pemphigoid (BP). A review of the patients’ previous medical records showed that the diagnosis was based on direct immunofluorescence studies of a biopsy section which revealed the deposition of immunoglobulin G (IgG) and C3 at the DEJ in a linear pattern.

We performed a comprehensive metabolic panel which was within normal limits. Pemphigoid circulating antibodies (BPAG 180 and BPAG230) and antinuclear antibodies (ANA) were all negative and C3 and C4 were within the normal range. An esophago-gastro-duodenoscopy showed extensive erosions on pharyngeal and upper-esophagus mucosa. No stricture or stenosis was detected. A colonoscopy was also performed but no signs of inflammatory bowel disease were detected. A thorough review of systems was entirely negative.

Two 4-mm punch biopsies were taken, one lesional for hematoxylin and eosin (H&E) and one perilesional for direct immunofluorescence (DIF). Standard histopathology with H&E showed subepidermal blistering with a neutrophil-rich infiltrate in the papillary dermis and within the bullous lesions. Mononuclear cells such as lymphocytes and monocytes could also be observed. Discrete fibrous changes of vascular hyperplasia were present in the superficial dermis, representing the histopathological correlation of the clinical scarring (Figure 6).
FIGURE 6: Microscopy image (Hematoxylin and Eosin staining) showing subepidermal blistering and a neutrophil-rich infiltrate in the papillary dermis and within the bullous lesion

Direct immunofluorescence tests showed linear deposits of IgG and C3 at the DEJ. IgA tested negative. Fibrinogen was positive in the cleavage area (non-specific finding). The "salt-split skin" technique showed the localization of the immunoreactants, mainly IgG, along the dermal side of the artificially induced blisters at the level of lamina lucida (Figure 7).
These findings supported the clinical diagnosis of EBA. We initiated treatment with 50 mg of dapsone per day. This resulted in decreased formation of new blisters. However, disease activity has persisted.

### Discussion

The two most common forms of EBA are: (1) the classical (non-inflammatory) type and (2) the inflammatory type, subsequently divided into various subtypes: (i) BP-like EBA; (ii) clinically mimicking cicatricial pemphigoid-like; (iii) linear IgA bullous dermatosis (LABD)-like; (iv) and Brunsting-Perry pemphigoid-like. The two most common presentations are the classical non-inflammatory EBA and the BP-like EBA [2].

The classical form is characterized by tense blisters and erosions without clinically associated inflammation. It is usually localized towards trauma-prone areas. Millia and scarring are common findings. In severe cases, nail loss, fibrosis of the fingers and esophageal stenosis may occur. In contrast, the inflammatory form is characterized by vesiculobullous disseminated eruptions with a predilection for the trunk, intertriginous areas, and extremities. The tense bullae develop on erythematous, inflamed basis [3]. Mucosal lesions are frequent in both classical and inflammatory EBA and both ocular and gastrointestinal mucosa can be affected in various degrees [4].

From the clinical features, we initially considered our patient as having classical non-inflammatory type EBA. But histopathology showed numerous neutrophils within the subepidermal blisters as well as in the interstitial infiltrate, pointing towards an inflammation-rich form [5]. Considering both the clinical and histopathological aspects, we hypothesized that our patient suffered from an atypical form of EBA, a mixed form that seems to have resulted from an overlap between the classical and the inflammatory forms. A possible explanation for this mixed clinical phenotype would be the epitope spreading phenomenon that has been extensively investigated in autoimmune skin diseases. Numerous epitopes on the N-terminal domain of type VII collagen are identified by circulating autoantibodies in patients with EBA and reactivity with various epitopes can induce different clinical phenotypes [2,6].
We conclude that in the case of EBA, and in other rare diseases in general, current knowledge could be limited by the lack of well-designed or large studies such as randomized control trials investigating treatment options for these diseases. Some improvements have been documented with immunosuppressive agents [18]. Long-term systemic glucocorticoids have proven to be less effective for EBA than for other blistering disorders. Some improvements have been documented with immunosuppressive agents [18]. For the previous three years, our patient had received treatment with oral glucocorticoids and systemic immunosuppressive medications, including azathioprine, cyclosporine or methotrexate, with no significant improvement. Thus, we preferred a different approach to initial therapy. We initiated treatment with dapsone, since treatment recommendations for most patients consist of colchicine or dapsone, in monotherapy or in combination [18-19]. For patients with EBA refractory to colchicine and dapsone, rituximab, an anti-CD20 monoclonal antibody, is a promising option but the high costs represent a major barrier in the use of these agents for patients with EBA [14].

A curative treatment for EBA does not currently exist. Hence, the goal of treatment is long-term remission of the disease. It usually has a prolonged course [18].

Conclusions

We conclude that in the case of EBA, and in other rare diseases in general, current knowledge could be...
enriched with the discovery of additional clinical phenotypes that at the moment may be under-diagnosed or under-reported in the literature. Further studies will be required to clarify whether our findings are simply hypothetical or purely incidental, or if EBA is indeed a disease with further various subtypes to be unraveled and well-established.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**